Clinical use in COVID-19
JAK-inhibitors are under investigation for their potential role in regulating the overactive signalling in the JAK-STAT pathway seen during cytokine storm in critically ill COVID-19 patients. Baricitinib with its potential to inhibit clathrin-mediated endocytosis and its ability to ameliorate associated chronic inflammation in interferonopathies is expected to show promising results in ongoing clinical trials of COVID-19 (154,155).